Assuit University
Asyut, 088, Egypt
NCT Number: NCT06577168
The purpose of this study is to systematically calculate the mean number of bleeding-only, spotting-only, and bleeding and/or spotting days experienced by a population of reproductive aged,52 mg levonogestrel Intrauterine System(LNG-IUS) users.
Trial opening soon.
Get Notified18 year–45 year
Female
Observational
Asyut, 088, Egypt
The levonogestrel Intrauterine system (LNG-IUS)(52 mg per 20mg per day release) is associated with medically benign changes to the menstrual pattern. Amenorrhea, the complete cessation of vaginal bleeding for at least 90 consecutive days, is perhaps the most extreme bleeding pattern experienced by some users during the first year. Amenorrhea prevalence is positively associated with duration of use, with approximately 8% of users.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
insertion
Exclusion criteria
Contraception method
Time frame: Six months after insertion of levonogestrel Intrauterine system
This include calculating the average number of days per month with bleeding-only, spotting-only,and bleeding and/or spotting in reproductive aged women using a 52 mg levonogestrel Intrauterine system (LNG-IUS) within the first six months ofuse, according to World Health Organization standards.
Contact information is provided by the study sponsor or research team.
Ahmed M Alaa eldin, Professor
CONTACT
Mariam S Lotfy
CONTACT
Assiut University
Other
The Prevalence and Predictors of Menstrual Pattern Within Six Months of Levonogestrel IUS Insertion.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07711717
Contraception
Kampala, Uganda
View Trial DetailsNCT07714616
Contraception
View Trial DetailsNCT07516548
Blood-Borne Infections, Communicable Diseases
Bontleng, Gaborone, Botswana
View Trial DetailsNCT07597824
Blood-Borne Infections, Communicable Diseases
Bontleng, Gaborone, Botswana
View Trial Details